New FDA CMC Draft Guidance Released for Personalized Antisense Oligonucleotide Products
Many patients rely on personalized medicine like antisense oligonucleotide (ASO) products for complex or treatment-resistant conditions. Meeting the needs of [...]
Advertisement
